It is noteworthy that while there was no significant difference in a RFS rate between 20 patients having a HR+ or HR- tumor with aberrations of the PI3K pathway genes and 22 patients having a HR+ or HR- tumor with no such aberrations (Table 3 and Figure 2C, P=0.195), 13 patients having a HR+ tumor with the same aberrations had a worse RFS rate than 12 patients having a HR+ tumor with no such aberrations (Table 4, Figure 2D, P=0.002). Here, PIK3CA is linked to neoplasm.